A multi-center, randomized, double-blind, double-dummy study in postmenopausal women with low bone mineral density to compare the effects of a single dose of i.v. [intravenous] zoledronic acid 5 mg, with daily oral raloxifene 60 mg OD [once daily] on bone turnover markers.

Trial Profile

A multi-center, randomized, double-blind, double-dummy study in postmenopausal women with low bone mineral density to compare the effects of a single dose of i.v. [intravenous] zoledronic acid 5 mg, with daily oral raloxifene 60 mg OD [once daily] on bone turnover markers.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2011

At a glance

  • Drugs Raloxifene; Zoledronic acid
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Sep 2009 Results presented at the 31st Annual Meeting of the American Society for Bone and Mineral Research.
    • 16 Dec 2008 Actual trial completion date identified as July 2008 from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top